Charles River Laboratories (NYSE:CRL) FY Conference January 13, 2026 01:30 PM ET Company ParticipantsJames C. Foster - CEOConference Call ParticipantsCasey Woodring - AnalystNoneYeah.Casey WoodringHi, everybody. Welcome to the J.P. Morgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Charles River Labs CEO, Jim Foster. Jim's going to give the corporate presentation, then we'll jump right into Q&A afterwards. Jim, the floor is yours.James ...

Key Takeaways Charles River Laboratories International, Inc. (CRL) reported second-quarter 2025 adjusted earnings per share (EPS) of $3.12, which rose 11.4% year over year. The figure surpassed the Zacks Consensus Estimate by 24.8%. On a GAAP basis, the company reported earnings of $1.06 per share compared with the year-ago quarter's level of $1.74. CRL's Q2 Revenues Revenues totaled $1.03 billion, which beat the Zacks Consensus Estimate by 5%. The top line rose 0.6% from the year-ago quarter's level (down ...